TPS ELISA is an in vitro diagnostic assay intended for quantitative determination of cytokeratin 18 in serum during cancer therapy monitoring and patient follow-up. Performance characteristics are well defined for patients with epithelial cancers, e.g. breast, prostate and ovarian cancer.

Our IBL TPS ELISA is a one step enzyme linked sandwich immunoassay. Standards, controls and samples react during incubation simultaneously with a solid phase monoclonal catcher antibody and the HRP-conjugated detector antibody (M3). After washing, the TMB substrate is added and after an incubation time the reaction is stopped and the absorbance at 450 nm is measured. The developed colour is directly proportional to the concentration of the analyte.

The IBL TPS ELISA measures the M3-epitope on cytokeratin 18 fragments. There is no detectable cross reactivity to cytokeratin 8 and 19.